Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/CEOR.S100921 http://scihub22266oqcxt.onion/10.2147/CEOR.S100921 C4762464!4762464!26937203     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clinicoecon+Outcomes+Res 2016 ; 8 (ä): 43-52 Nephropedia Template TP {{tp|p=26937203|t=2016. Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center |pdf=|usr=}}{{26937203}} gab.com Text Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center JO: Clinicoecon Outcomes Res http://www.kidney.de/pget.php?&tw=1&pmid=26937203 #FOAvip Objective: The aim of the study is to evaluate the clinical and economic impact of introducing a rocuronium?neostigmine?sugammadex strategy into a cisatracurium?neostigmine regimen for neuromuscular block (NMB) management. Methods: We conducted a retrospective analysis of clinical outcomes and cost-effectiveness in five operating rooms at University Hospital of Padova. A clinical outcome evaluation after sugammadex administration as first-choice reversal drug in selected patients (rocuronium?sugammadex) and as rescue therapy after neostigmine reversal (rocuronium?neostigmine?sugammadex) compared to control was performed. A cost-analysis of NMB management accompanying the introduction of a rocuronium?neostigmine?sugammadex strategy into a cisatracurium?neostigmine regimen was carried out. To such purpose, two periods were compared: 2011?2012, without sugammadex available; 2013?2014, with sugammadex available. A subsequent analysis was performed to evaluate if sugammadex replacing neostigmine as first choice reversal drug is cost-effective. Results: The introduction of a rocuronium?neostigmine?sugammadex strategy into a cisatracurium?neostigmine regimen reduced the average cost of NMB management by 36%, from ?20.8/case to ?13.3/case. Patients receiving sugammadex as a first-choice reversal drug (3%) exhibited significantly better train-of-four ratios at extubation (P<0.001) and were discharged to the surgical ward (P<0.001) more rapidly than controls. The cost-saving of sugammadex as first-choice reversal drug has been estimated to be ?2.9/case. Patients receiving sugammadex as rescue therapy after neostigmine reversal (3.2%) showed no difference in time to discharge to the surgical ward (P=0.44) compared to controls. No unplanned intensive care unit (ICU) admissions with rocuronium?neostigmine?sugammadex strategy were observed. The potential economic benefit in avoiding postoperative residual curarization (PORC)-related ICU admission in the 2013?2014 period was estimated at an average value of ?13,548 (?9,316??23,845). Conclusion: Sugammadex eliminated PORC and associated morbidities. In our center, sugammadex reduced the costs of NMB management and promoted rapid turnover of patients in operating rooms, with total cost-effectiveness that counteracts the disadvantages of its high cost. Twit Text FOAVip Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center ????Clinicoecon Outcomes Res http://www.kidney.de/pget.php?&tw=1&pmid=26937203 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26937203 #FOAvip English Wikipedia <ref>{{Cite pmid|26937203}}</ref> Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center #MMPMID26937203 Carron M; Baratto F; Zarantonello F; Ori C Clinicoecon Outcomes Res 2016[]; 8 (ä): 43-52 PMID26937203show ga Objective: The aim of the study is to evaluate the clinical and economic impact of introducing a rocuronium?neostigmine?sugammadex strategy into a cisatracurium?neostigmine regimen for neuromuscular block (NMB) management. Methods: We conducted a retrospective analysis of clinical outcomes and cost-effectiveness in five operating rooms at University Hospital of Padova. A clinical outcome evaluation after sugammadex administration as first-choice reversal drug in selected patients (rocuronium?sugammadex) and as rescue therapy after neostigmine reversal (rocuronium?neostigmine?sugammadex) compared to control was performed. A cost-analysis of NMB management accompanying the introduction of a rocuronium?neostigmine?sugammadex strategy into a cisatracurium?neostigmine regimen was carried out. To such purpose, two periods were compared: 2011?2012, without sugammadex available; 2013?2014, with sugammadex available. A subsequent analysis was performed to evaluate if sugammadex replacing neostigmine as first choice reversal drug is cost-effective. Results: The introduction of a rocuronium?neostigmine?sugammadex strategy into a cisatracurium?neostigmine regimen reduced the average cost of NMB management by 36%, from ?20.8/case to ?13.3/case. Patients receiving sugammadex as a first-choice reversal drug (3%) exhibited significantly better train-of-four ratios at extubation (P<0.001) and were discharged to the surgical ward (P<0.001) more rapidly than controls. The cost-saving of sugammadex as first-choice reversal drug has been estimated to be ?2.9/case. Patients receiving sugammadex as rescue therapy after neostigmine reversal (3.2%) showed no difference in time to discharge to the surgical ward (P=0.44) compared to controls. No unplanned intensive care unit (ICU) admissions with rocuronium?neostigmine?sugammadex strategy were observed. The potential economic benefit in avoiding postoperative residual curarization (PORC)-related ICU admission in the 2013?2014 period was estimated at an average value of ?13,548 (?9,316??23,845). Conclusion: Sugammadex eliminated PORC and associated morbidities. In our center, sugammadex reduced the costs of NMB management and promoted rapid turnover of patients in operating rooms, with total cost-effectiveness that counteracts the disadvantages of its high cost. äSugammadex for reversal of neuromuscular blockade: a retrospective ana(epmc).pdf DeepDyve Pubget Overpricing